Early lesions of follicular lymphoma: a genetic perspective

Similar documents
Supplementary Figure 1

Dako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis)

Hematopathology Service Memorial Sloan Kettering Cancer Center, New York

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

p.r623c p.p976l p.d2847fs p.t2671 p.d2847fs p.r2922w p.r2370h p.c1201y p.a868v p.s952* RING_C BP PHD Cbp HAT_KAT11

HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer

ACMG/CAP Cytogenetics CY

CLL Complete SM Report

IT S ABOUT TIME. IQFISH pharmdx Interpretation Guide THREEHOURSTHIRTYMINUTES. HER2 IQFISH pharmdxtm. TOP2A IQFISH pharmdxtm

Supplementary Information Titles Journal: Nature Medicine

Molecular Probes Introducing 14 new probes

Role of FISH in Hematological Cancers

Oncology Genetics: Cytogenetics and FISH 17/09/2014

Vysis ALK Break Apart FISH Probe Kit

Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method

Transform genomic data into real-life results

Three Hours Thirty Minutes

Assessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray

Supplementary Appendix

(A) PCR primers (arrows) designed to distinguish wild type (P1+P2), targeted (P1+P2) and excised (P1+P3)14-

Cytogenetics 101: Clinical Research and Molecular Genetic Technologies

Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique

iplex genotyping IDH1 and IDH2 assays utilized the following primer sets (forward and reverse primers along with extension primers).

Supplementary methods:

Supporting Information Table of Contents

HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer

Supporting Online Material for

Detection of Circulating Tumor Cells Harboring a Unique ALK-Rearrangement in ALK- Positive Non-Small-Cell Lung Cancer.

Methods used to diagnose lymphomas

I have no relevant conflicts of interest to disclose. John T. Seykora MD PhD Departments of Dermatology & Pathology and Laboratory Medicine

Instant Quality FISH. The name says it all.

ExpressArt FFPE Clear RNAready kit

ABBOTT MOLECULAR ONCOLOGY AND GENETICS

Structural Variation and Medical Genomics

Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research

High-Grade B-cell Lymphoma Double Hit or Double Expressing

Introduction to LOH and Allele Specific Copy Number User Forum

EPIGENETIC RE-EXPRESSION OF HIF-2α SUPPRESSES SOFT TISSUE SARCOMA GROWTH

OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies

Determination of Genomic Imbalances by Genome-wide Screening Approaches

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

Supplementary Figure 1. Spitzoid Melanoma with PPFIBP1-MET fusion. (a) Histopathology (4x) shows a domed papule with melanocytes extending into the

Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota

at least 5 probes standard 8 probes (13, 15, 16, 18, 21, 22, 15, X, Y) at least 5 probes standard 8 probes (13, 15, 16, 18, 21, 22, X, Y)

Priti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract

ncounter TM Analysis System

NGS IN ONCOLOGY: FDA S PERSPECTIVE

Molecular Diagnosis. Nucleic acid based testing in Oncology

Nucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis

Composite mantle cell and follicular lymphoma. A case report

S1 Appendix: Figs A G and Table A. b Normal Generalized Fraction 0.075

Figure S2. Distribution of acgh probes on all ten chromosomes of the RIL M0022

Comprehensive Analyses of Circulating Cell- Free Tumor DNA

CANCER. Clinical Validation of Breast Cancer Predictive Markers

UNIVERSITI TEKNOLOGI MARA COPY NUMBER VARIATIONS OF ORANG ASLI (NEGRITO) FROM PENINSULAR MALAYSIA

Genetic alterations of histone lysine methyltransferases and their significance in breast cancer

HER2 ISH (BRISH or FISH)

GENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute

Rearrangement of the ALK gene occurs in approximately

HSL-Advanced Diagnostics 2018 / 19 Test & Service List

Supplementary Figure S1. Gene expression analysis of epidermal marker genes and TP63.

Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010

T he HER2/neu type 1 tyrosine kinase growth factor

Supplementary Information for. Shi and King, Chromosome Nondisjunction Yields Tetraploid Rather than Aneuploid Cells in Human Cell Lines.

Nature Medicine: doi: /nm.3967

TITLE: The Role of hcdc4 as a Tumor Suppressor Gene in Genomic Instability Underlying Prostate Cancer

Nature Genetics: doi: /ng Supplementary Figure 1. Mutational signatures in BCC compared to melanoma.

FISH VALIDATION: HOW I DO IT!

Lentiviral Delivery of Combinatorial mirna Expression Constructs Provides Efficient Target Gene Repression.

Volume 7, Issue 1 January 2012

Clinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma

Understanding the Human Karyotype Colleen Jackson Cook, Ph.D.

5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff

Supplementary Information

Application of Whole Genome Microarrays in Cancer: You should be doing this test!!

Nationwide Children s Hospital Biospecimen Core Resource Training

Introduction. Introduction

Integrated Analysis of Copy Number and Gene Expression

American Society of Cytopathology Core Curriculum in Molecular Biology

NGS ONCOPANELS: FDA S PERSPECTIVE

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute

Genomic structural variation

Hematopathology Case Study

Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?

SUPPLEMENTARY INFORMATION

Nature Biotechnology: doi: /nbt.1904

American Society of Cytopathology Core Curriculum in Molecular Biology

Gastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR

An Overview of Cytogenetics. Bridget Herschap, M.D. 9/23/2013

Patnaik SK, et al. MicroRNAs to accurately histotype NSCLC biopsies

(Fully automated FISH Analysis for B-cell Chronic Lymphocytic Leukemia: a faster alternative to manual double scoring)

Personalized Medicine: Lung Biopsy and Tumor

Use of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma

Human Cancer Genome Project. Bioinformatics/Genomics of Cancer:

Nature Genetics: doi: /ng Supplementary Figure 1. Somatic coding mutations identified by WES/WGS for 83 ATL cases.

Protein SD Units (P-value) Cluster order

SALSA MLPA probemix P315-B1 EGFR

Transcription:

Non-Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Early lesions of follicular lymphoma: a genetic perspective Emilie Mamessier, 1 Joo Y. Song, 2 Franziska C. Eberle, 2 Svetlana Pack, 2 Charlotte Drevet, 1 Bruno Chetaille, 3 Ziedulla Abdullaev, 2 José Adelaïde, 4 Daniel Birnbaum, 4 Max Chaffanet, 4 Stefania Pittaluga, 2 Sandrine Roulland, 1 Andreas Chott, 5 Elaine S. Jaffe, 2 * and Bertrand Nadel 1 * 1 CIML, Genomic Instability and Human Hemopathies, Marseille, France; 2 National Institutes of Health, Laboratory of Pathology, Bethesda, USA; 3 IPC, Laboratory of Pathology, Marseille, France; 4 IPC, Molecular Oncology, Marseille, France; and 5 Wilhelminenspital, Institute of Pathology and Microbiology, Vienna, Austria Current affiliation of FCE: Department of Dermatology, Eberhard Karls University, Tübingen, Germany *ESJ and BN contributed equally to this work. 2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.094474 Manuscript received on July 3, 2013. Manuscript accepted on October 21, 2013. Correspondence: elainejaffe@nih.gov or nadel@ciml.univ-mrs.fr

Supplemental Material and Methods Online Supplemental Revised tables 1-6 uploaded as Excel files Samples Most cases were selected from FFPE archived specimens submitted to the Hematopathology Section at the National Cancer Institute (NCI) for consultation, from 1999 through 2011. Seven cases of FLIS and 5 cases of PFL (all Grade 1-2), with suitable material were identified based on previously published criteria (12). Patients with FLIS and PFL had no other evidence of disease during the period of follow-up; 3 of 7 FLIS (#1, #2, and #4) were included in a previously published series (12). Five cases of DFL were obtained from the archival files of the Institute of Pathology, Medical University Vienna, Austria, collected from January 1997 to April 2008, as previously reported by Schmatz et al (11). The principal cohort of FLIS, PFL and DFL was compared to 5 cases of FL Grade 1-2 and 5 cases of FL Grade 3A included as controls of the most frequent alterations occurring in low grade and presumptively more advanced FL. Finally, reactive follicular hyperplasia sections (RFH, n=2) and laser micro-dissected lymphoid cells from uninvolved areas of one FLIS (FLIS background) were also hybridized and used as reference for normal (non-neoplastic) cells (Supplemental Table 1). Only cases with confirmed t(14; 18) were included in the study. The Institutional Review Boards of the National Cancer Institute and the Medical University of Vienna approved the study. FISH validation at the 1p36, 7p and 12q loci, and FISH analysis of the BCL2 gene rearrangements on paraffin-embedded tissue sections Deletion in the 1p36, amplifications in the 7p and 12q loci, and BCL2 gene rearrangement status were assessed using Fluorescence In Situ Hybridization (FISH). For BCL2 interphase FISH analysis, BCL2 Split Signal FISH DNA Probe, (DAKO, Denmark, Code Y5407) was used. FISH for 1p36, 7p12, 12q 13.3-14.1 chromosomal regions was performed using Vysis probes Vysis LSI 1p36 / LSI 1q25 Dual-Color Probe covering MEGF6 and TP73 genes for Chr. 1p36 region, Vysis LSI EGFR SpectrumOrange/ CEP 7 SpectrumGreen Probe (Abbott Molecular, Chicago, IL) for Chr 7p12, and custom-made probe for Chr. 12q13.3-14.1 region

using RP11-571M6 BAC clone (that includes CDK4 locus and 11 more genes) labeled with Red-5-ROX dutp combined with the control centromeric probe for chromosomes 12 labeled with Green-5-Fluorescein ( Empire Genomics, Buffalo, NY). FISH assays were performed on 5 micron Formalin-Fixed-Paraffin-Embedded (FFPE) tumor sections using laboratory standardized protocol with slight modifications (17). In brief, 5 µm thick sections of FFPE tissue blocks were de-paraffinized, and rehydrated. Antigen retrieval was performed with IHC-Tek Epitope Retrieval Solution (IHC World, Woodstock, MD) with steaming for 25 min. After cooling, slides were subjected to 50 µkg/ml pepsin treatment at 37 o C, rinsed in PBS solution followed by dehydration in ethanol series. Co-denaturation of the probe and target DNA at 73 o C in HYBrite (Abbott Molecular, Chicago, IL) for 5 min was followed by overnight hybridization at 37 o C. The next day, slides were washed at 72 o C in 0.4X SSC/0.3% Tween-20 for 2 min and then in 2X SSC/0.1% Tween-20 at room temperature for 1 min. The slides were counterstained, mounted with DAPI/Antifade (Vector Laboratories, Burlingame, CA) and analyzed on the BioView Duet-3 fluorescent scanning station using 63X-oil objective and DAPI/FITC/Rhodamine single-band pass filters (Semrock, Rochester, NY). At least 100 tumor cell nuclei were scored for each specimen. The cutoff >10% was applied for the cells with the split Red and Green fluorescence signals to be scored as positive for BCL2 gene rearrangement. For 1p deletion, ratio of 1p-Red/1q-Green signals <0.8 was scored as positive for a 1p36 deletion. For 7p and 12q copy number gain presence of >3 signals in more than 40% of cells, as well as ratio Red/Green signal>1.3 was scored as copy number gain, while ratio >2 was indicative of focal amplification. Transcription profiling public dataset Public Affymetrix U133+2 data sets from purified Resting, Naïve, GC, memory and FL B cells were retrieved from the public GEO datasets GSE12195 (http://www.ncbi.nlm.nih.gov/gds). We used Robust Multichip Average (RMA) with the non-parametric quantile algorithm as normalization parameter. RMA was applied to the raw data, and quantile normalization and Loess correction were done in R using Bioconductor and associated packages. The probesets corresponding to the gene of interest were retrieved from the normalized data sets and the corresponding log values were linearized for graphical representation. Ontology and pathway analyses were submitted to Ingenuity and DAVID s database for annotation, visualization, and integrated discovery. Sanger Sequencing

DNA from FLIS (n = 7), DFL (n=4), PF (n=3)l, FL (n = 6) and RFH (n=5 ) samples was used to analyze all exons of TNFRSF14 genes, exons 25-30 of the CREBBP gene, and Exon 15 of the EZH2 gene by PCR amplification. Sequencing was performed by Eurofins MWG Operon (Ebersberg, Germany). Mutations were sequenced twice from different PCR reactions to verify the aberration. Primers pairs are listed below: TNFRSF14 Exon 1: TGAGCTAGGTCTGGGTTGACCCGAGA/ CTCTGCTGGAGTTCATCCTG TNFRSF14 Exon 2: CCCAGGGCTTCATCACAC / CCCAAGTGCAGTCCAGGTAG TNFRSF14 Exon 3: CACTGTGGCCATGGAGAGAG / GGCCATTTGAGTCCCCTTAG TNFRSF14 Exon 4: TCTCTGTCCTGGAGCAGTTC / CTCCCAGGACCTTCCTGCAA TNFRSF14 Exon 5: TGCTGGAGAAGACGGTCAT / GGTCTAGAAGCTCACAGACA TNFRSF14 Exon 6: GCTTTCTTCTTTTCACACATATGATTAG/ CTGGGACCTGTCTTCACTG TNFRSF14 Exon 7: TGAGCTACCGTGGCTGTACT / GTGTATTGCAGGTGATGTAG TNFRSF14 Exon 8: GAAAACAGGAGCCGAATTC / TGGGTTGGCTGCAGTGTG CREBBP Exon 25: GGACACTTAAGAGCCCTGGTC/ CATTCACAGAGGTGCAGTTCC CREBBP Exon 26: CACCTGGAAAGAGGAGCTTTG/ CAGGGTGTTGTTTGTTGCTTG CREBBP Exon 27: CTCCAACTGTGCTGCTCTCAG/ TCCTGGCTTTAGTCCTTGCTC CREBBP Exon 28: AGGACCTAACAGTCGACACGC/ CACACATGCATGGGACTCTG CREBBP Exon 29: ACTTCCCTCCCACCACAGAC/GTGACCTACTTTGGCCTGAGC CREBBP Exon 30: CAGCCACCATCAGGTACAGAC/CTCAGCCACCTGCCTATTCTG EZH2_Exon 15: TCTCAGCAGCTTTCACGTTG/ CAGGTTATCAGTGCCTTACCTCTCC Statistics Groups were compared using non parametric unpaired Mann & Whitney t-test. Only p-values inferior to 0.05 were considered as significant. * : p < 0.05

A. i. ii. iii. B. 7p12 C. 12q12-15 12p11 CEP12 Green-Fluorescein 12q13.3-q14.1 Red-Rox 12 D. 1p36red-1qgreen Figure S1. FISH validation for BCL2 gene rearrangements in early FL entities with and without copy number variations.

Figure S2. FISH validation for BCL2 gene rearrangements in early FL entities with and without copy number variations. A. Dual-color Interphase FISH on FFPE tissue sections using BCL2 split signal probe showing BCL2 gene rearrangement that results in split red and green fluorescence signals. Cells with rearranged BCL2 gene are marked by arrowheads. Cells having BCL2 gene rearrangement and CNV are depicted by long arrows (i, ii) i. PFL #4 (left panel). Cell at lower left contains two fused signals, two red and two green split signals 2F/2R/2G, indicative of additional copies of wild type and rearranged BCL2. ii. PFL #2 (center panel). One normal cell in center of the field contains two fused signals, 2F (normal diploid), whereas PFL cells contain 3-4 fused signals and one red, one green split signals 3-4F/1R/1G (arrow). iii. FLIS #4 (right panel). FLIS cells without CNV contain one normal fused signal, one red and one green split signals, 1F/1R/1G. Abbreviations: CNV, gain of BCL2 copy number; F, fused; R, red; G, green. B-D. Amplifications of the 7p14 region were confirmed on the PFL#2 sample, as well as on all available FL 1-2 (n = 1) and FL 3A (n = 4) samples displaying this alteration. A representative example of FISH result is shown in B. Amplifications of the 12q12-13 and 12q15 regions were confirmed on the PFL#1 sample, as well as on available FL 1-2 (n = 3) and FL 3A (n = 3) samples displaying this alteration. A representative example of FISH result is shown in C. Losses of the 1p36 region were confirmed on the PFL#2 sample, as well as on available FL 3A samples displaying this alteration (n = 2). A representative example of FISH result is shown in D. A. i. ii. iii.

B. 7p14 C. 12q12-15 12p11 CEP12 Green-Fluorescein 12q13.3-q14.1 Red-Rox D. 1p36red-1qgreen 12

Figure S3. Mean number of gained and lost segments per sample in early-fl entities and FL samples. Controls FLIS DFL PFL FL 1/2 FL 3A

Figure S4. Selected examples of focal gains in microdissected FLIS samples (orange and pink) versus their backgrounds (grey). Some of these alterations involved GC-related genes (AFF3, EBF1, BACH2, TOX). -4 0 +4-4 0 +4-3 -2-1 +1 +2 +3-3 -2-1 +1 +2 +3 AFF3 EBF1 K2 K5 BACH2 TOX K6 K11

Figure S5. mrna expression of candidates (identified by CGH) in overt FL samples. A. Genes found in altered regions from PFL, FLIS and FL samples. B. Oncogenes (previously involved in NHL lymphomagenesis) found in PFL. C. Oncogenes amplified in DFL samples. A B C

Figure S6. CGH profile of the chromosome 1, showing the loss at the 1p36 locus in PFL and DFL samples. In total, loss of the 1p36 locus are found in 17% of early-fl samples. PFL (A) and DFL (B) samples are in colors (Blue and purples shades respectively). Genes of interested covered in this region (TNFRSF14, TP73 and TNFRSF25) are indicated with black arrows A -1 0 +1-1 0 +1 TNFRSF14 TP73 TNFRSF25 K1 B -1 0 +1-1 0 +1 TNFRSF14 TP73 TNFRSF25 K1

Figure S7. Mean number of alterations between 100 and 700kb (gains and losses) in early-fl and FL 120 Gains Losses Mean number of alteration / sample 100 80 60 40 20 0 Controls FLIS DFL PFL FL 1/2 FL 3A

t(14;18)+ frequency Figure S8. 1 10-1 10-2 10-3 10-4 10-5 10-6 10-7 Progression phase of t(14;18)+ cells to FL diagnosis Weak Strong BCL2 staining intensity Antigen dependency Proliferation Index GC-(environment) dependency Lymph node architectural distortion Frozen GC features Normal GC-experienced t(14;18)+ Memory B cells Allelic paradox On going AID-mediated activity (including off-target mutations)?? CNV (GC related genes) Major Genomic Alterations Gains Losses FL PFL FLIS FL-like B cells t(14;18) Detection limit t(14;18)+ B cells